Metraipolis › archive › dc_3acff453e503
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study — Europe PMC PMID:34928960
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/34928960
- DOI
- 10.1371/journal.pmed.1003872
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-31T21:33:54.267Z
- SHA-256 of the archived text
26133c5283fc47860a4ad364fe00e8799434ffa4c0c281c5122c64031e4ae120- Stable URL of this page
https://metraipolis.com/documento/dc_3acff453e503
How to cite
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study — Europe PMC PMID:34928960 — Europe PMC (en), https://europepmc.org/article/MED/34928960 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_3acff453e503 (Metraipolis archive dc_3acff453e503, sha256 26133c5283fc47860a4ad364fe00e8799434ffa4c0c281c5122c64031e4ae120)
BibTeX
@misc{dc3acff453e503,
title = {Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study — Europe PMC PMID:34928960},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/34928960},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_3acff453e503; sha256 26133c5283fc47860a4ad364fe00e8799434ffa4c0c281c5122c64031e4ae120},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34928960. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized clinical trials were in various stages of development and enrollment, there was an urgent need for widespread access to potential therapeutic agents. The objective of this study is to report on the demographic, geographical, and chronological characteristics of patients in the EAP, and key safety metrics following transfusion of COVID-19 convalescent plasma. Methods and findings: Mayo Clinic served as the central institutional review board for all participating facilities, and any US physician could participate as a local physician-principal investigator. Eligible patients were hospitalized, were aged 18 years or older, and had-or were at risk of progression to-severe or life-threatening COVID-19; eligible patients were enrolled through the EAP central website. Blood collection facilities rapidly implemented programs to collect convalescent plasma for hospitalized patients with COVID-19. Demographic and clinical characteristics of all enrolled patients in the EAP were summarized. Temporal patterns in access to COVID-19 convalescent plasma were investigated by comparing daily and weekly changes in EAP enrollment in response to changes in infection rate at the state level. Geographical analyses on access to convalescent plasma included assessing EAP enrollment in all national hospital referral regions, as well as assessing enrollment in metropolitan areas and less populated areas that did not have access to COVID-19 clinical trials. From April 3 to August 23, 2020, 105,717 hospitalized patients with severe or life-threatening COVID-19 were enrolled in the EAP. The majority of patients were 60 years of age or older (57.8%), were male (58.4%), and had overweight or obesity (83.8%). There was substantial inclusion of minorities and underserved populations: 46.4% of patients were of a race other than white, and 37.2% of patients were of Hispanic ethnicity. Chronologically and geographically, increases in the number of both enrollments and transfusions in the EAP closely followed confirmed infections across all 50 states. Nearly all national hospital referral regions enrolled and transfused patients in the EAP, including both in metropolitan and in less populated areas. The incidence of serious adverse events was objectively low (<1%), and the overall crude 30-day mortality rate was 25.2% (95% CI, 25.0% to 25.5%). This registry study was limited by the observational and pragmatic study design that did not include a control or comparator group; thus, the data should not be used to infer definitive treatment effects. Conclusions: These results suggest that the EAP provided widespread access to COVID-19 convalescent plasma in all 50 states, including for underserved racial and ethnic minority populations. The study design of the EAP may serve as a model for future efforts when broad access to a treatment is needed in response to an emerging infectious disease. Trial registration: ClinicalTrials.gov NCT#: NCT04338360. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS medicine, 2021 (prima pubblicazione 2021-12-20). Identificativi: PMID 34928960 · PMCID PMC8730442 · DOI 10.1371/journal.pmed.1003872. Descrittori MeSH principali: Registries. Pagina: https://europepmc.org/article/MED/34928960 — https://doi.org/10.1371/journal.pmed.1003872. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-31T21:24:25.739Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.